Moreover, dasatinib, which targets LYN and FYN in the TCR pathway, was initially reported to improve the survival of AITL model mice and achieved an 80% (4/5) ORR in patients with R/R AITL (68). This evidence concerns the gene LYN and angioimmunoblastic T-cell lymphoma.